The efficacy of intra-articular triamcinolone acetonide 10 mg versus 40 mg in patients with osteoarthritis knee, a non-inferiority, randomized, controlled, double-blind study.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210224002

Enrollment

208

Registered

2021-02-24

Start date

2019-09-10

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary osteoarthritis of knee. Osteoarthritis of knee Triamcinolone acetonide Intraarticular steroid injection

Interventions

Triamcinolone acetonide 10 mg, intraarticular injection,Triamcinolone acetonide 40 mg, intraarticular injection

Experimental Drug,Active Comparator Drug

Triamcinolone acetonide 10 mg,Triamcinolone acetonide 40 mg

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with primary osteoarthritis of knee according to ACR criteria and age over 50 years old, which fail oral pain medication or contraindicated.

Exclusion criteria

Exclusion criteria: Contraindicated for intraarticular steroid injection, infection, bleeding diathesis. Previous intraarticular steroid injection in previous 3 months Secondary osteoarthritis of knee Patient who takes systemic steroid Knee with prosthesis Patient with schedules for TKA in 3 months from randomization

Design outcomes

Primary

Measure	Time frame
Pain score by VAS 4 and 12 weeks VAS	—

Secondary

Measure	Time frame
Thai WOMAC score 4 and 12 weeks Questionnaire,Thai KOOS 4 and 12 weeks Questionnaire,EQ5D 4 and 12 weeks Questionnaire,Global VAS 4 and 12 weeks VAS,Timed 20m walk 4 and 12 weeks Duration,Chair stand test 4 and 12 weeks Number	—

Countries

Thailand

Contacts

Public ContactKomchan Utamawatin

Phramongkutklao hospital

milano_bcc156@hotmail.com0865113539

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026